Korean pharmas race for generic P-CAB market amid Takeda's uncertain future for Vocinti
More than 20 Korean pharmaceutical companies are getting ready to grab the generic potassium-competitive acid blocker (P-CAB) market in response to a potential void left by Takeda Pharmaceutical's once-promising P-CAB, Vocinti (ingredient: vonoprozan). …